+DayWeekMonth−
Monday · Nov 9, 2026 · Health Digest · science

FDA approves Bayer's Sunharbo, the first factor XIa inhibitor, to cut repeat stroke risk

The approval was based on the OCEANIC-STROKE Phase 3 trial of 12,327 adults, in which Sunharbo 50 mg once daily cut the risk of ischemic stroke by 26% compared with placebo over a median treatment of 14.2 months, the FDA said. The overall rate of major bleeding was similar between the groups but higher with Sunharbo in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common, according to the agency.

The FDA said Sunharbo is not approved for stroke prevention in patients with atrial fibrillation. A 30-day supply will carry a list price of $748.50, a Bayer spokesperson told BioPharma Dive.

Why it matters: BioPharma Dive said it is the first U.S. approval for a new class of blood thinners that target the clotting protein factor XIa, which are designed to prevent harmful clots while preserving the body's ability to stop bleeding.

References

  1. FDA Approves First Factor XIa Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
    U.S. Food and Drug Administration · fda.gov · 2026-11-09
  2. Bayer wins FDA nod for a new kind of blood thinner
    BioPharma Dive · biopharmadive.com · 2026-11-09